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Abstract
Rationale: Epicardial Adipose Tissue (EAT) volume as determined by chest computed tomography (CT) is an independent
marker of cardiovascular events in the general population. COPD patients have an increased risk of cardiovascular disease,
however nothing is known about the EAT volume in this population.
Objectives: To assess EAT volume in COPD and explore its association with clinical and physiological variables of disease
severity.
Methods: We measured EAT using low-dose CT in 171 stable COPD patients and 70 controls matched by age, smoking
history and BMI. We determined blood pressure, cholesterol, glucose and HbA1c levels, microalbuminuria, lung function,
BODE index, co-morbidity index and coronary artery calcium score (CAC). EAT volume were compared between groups. Uni
and multivariate analyses explored the relationship between EAT volume and the COPD related variables.
Results: COPD patients had a higher EAT volume [143.7 (P25–75, 108.3–196.6) vs 129.1 (P25–75, 91.3–170.8) cm
3, p = 0.02)] and
the EAT volume was significantly associated with CAC (r = 0.38, p,0.001) and CRP (r = 0.32, p,0.001) but not with
microalbuminuria (r = 0.12, p = 0.13). In COPD patients, EAT volume was associated with: age, pack-years, BMI, gender,
FEV1%, 6 MWD, MMRC and HTN. Multivariate analysis showed that only pack-years (B = 0.6, 95% CI: 0.5–1.3), BMI (B = 7.8,
95% CI: 5.7–9.9) and 6 MWD (B=20.2, 95% CI: 20.3–20.1), predicted EAT volume.
Conclusions: EAT volume is increased in COPD patients and is independently associated with smoking history, BMI and
exercise capacity, all modifiable risk factors of future cardiovascular events. EAT volume could be a non-invasive marker of
COPD patients at high risk for future cardiovascular events.
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Introduction
Chronic obstructive pulmonary disease (COPD) and cardiovas-
cular diseases (CVD) are two of the top causes of death worldwide
[1]. COPD has been described as an independent risk factor for
CVD (2) and the latter is a major cause of mortality in COPD,
particularly in patients with mild to moderate disease [3–5].
Non-invasive CVD markers may be important to identify
COPD patients who are at high risk to develop future
cardiovascular events. Beyond the traditional non-invasive CVD
risk factors, several other have been proposed for COPD patients,
including C-Reactive Protein (CRP) [6], arterial stiffness evaluated
by pulse wave velocity (PWV) [7], carotid intima-media thickness
(IMT) [8], ankle-brachial index (ABI) [9], and microalbuminuria
(MAB) [10].
Epicardial Adipose Tissue (EAT) is the visceral thoracic fat
located between the myocardium and the visceral pericardium,
and given its anatomical proximity to the heart, EAT can locally
modulate the myocardium and coronary arteries [11]. Like other
white adipose tissue loci, EAT could function as a lipid-storing
depot, as an endocrine organ that secretes hormones, and as
inflammatory tissue that secretes cytokines and chemokines [12].
EAT volume can be quantified by different non-invasive
radiological techniques, such as echocardiography [13], magnetic
resonance imaging (MRI) [14], and computed tomography (CT)
[15]. Among available imaging modalities, volumetric quantifica-
tion of EAT with multidetector computed tomography (CT) has
been shown to be one of the most reliable and reproducible
methods to assess the amount of EAT [16]. Furthermore, the large
population based Multi-Ethnic Study of Atherosclerosis (MESA)
Study recently confirmed that EAT volume measured with a chest
CT, predicted incident coronary heart disease independent of
conventional risk factors [17].
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We hypothesized that patients with COPD would have larger
EAT volumes than appropriately matched controls, and that the
EAT volume in the COPD patients would relate to factors known
to increase risk for cardiovascular events. To test this hypothesis
we designed this cross sectional study that compared current and
former smokers with and without COPD, matched for age,
smoking history and body mass index (BMI).
Methods
Study Population
The institutional review board of the Clinica Universidad de
Navarra approved this study. Participants were former and current
smokers with and without COPD regularly seen in our pulmonary
clinic (Figure 1). They all signed the consent form approved by the
Human Review Board (Pamplona: ‘‘Comite´ de Etica de la
Investigacio´n, Universidad de Navarra IRB nu: 043/2006’’).
Subjects were consecutively enrolled from January 2002 to August
2012. COPD was defined by a history of smoking more than 10
pack-years and a post-bronchodilator FEV1/FVC less than 0.7.
To be enrolled, COPD patients had to be clinically stable for 8
weeks prior to entry, and receiving optimal therapy according to
international guidelines [18]. The non-COPD group was
comprised of smokers and former smokers with a smoking history
greater than 10 pack-years and without postbronchodilator airflow
obstruction (FEV1/FVC.0.7). All postbronchodilation measure-
ments were performed 15 minutes after the inhalation of 400 ug of
albuterol. Exclusion criteria were uncontrolled co-morbidities such
as malignancy or other confounding diseases. We recorded history
of diabetes mellitus, hypertension, dyslipidemia, and the use of
anti-hypertensive medications or statins. Blood pressure was
measured following standard recommendations [19].
Matching Process
Figure 1 shows the flow diagram of the matching process. From
the initial sample of 420 former and current smokers we identified
70 subjects without COPD and 350 with COPD. For the purpose
of this study we assigned former and current smokers without
COPD to the control group, and matched each control patient
with at least 2 COPD patients with similar age (62 years), pack-
years (63 pack-years), and BMI (63 units). Using the aforemen-
tioned criteria it was possible to properly match 70 controls with
171 COPD patients.
Clinical Variables
Lung volumes and spirometry were measured according to
ATS/ERS guidelines [20].
The 6-min walking distance (6 MWD) was selected from the
better of two walks separated by at least 30 minutes (21). Dyspnea
was evaluated by the modified Medical Research Council
(MMRC) scale [22]. BMI was calculated in kg/m2. The
FEV1%, BMI, 6 MWD and MMRC values were integrated into
the BODE index [23]. The Framingham Score was calculated as
previously described [24].
Laboratory Methods
Morning fasting blood and spot-urine samples were collected
simultaneously while at rest and before any other test. The
microalbuminuria (MAB) or urinary albumin excretion was
determined as the urinary albumin (milligrams) to creatinine
(grams) ratio in the morning urine. Urine albumin concentration
was determined by a standard turbidometric method (coefficient of
variation 5.5%). Serum and urine creatinine concentrations were
analyzed using the Jaffe reaction and quantified by a photometric
Figure 1. Flow diagram of the study population.
doi:10.1371/journal.pone.0065593.g001
Epicardial Adipose Tissue in COPD
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e65593
method. Fasting serum levels of glucose, high sensitivity CRP,
glycated haemoglobin (HbA1c) and cholesterol were also deter-
mined.
CT Image Acquisition and Reconstruction Protocol
All individuals underwent the CT examinations using a
multidetector CT (Somatom Definition and Somatom Sensation
64, Siemens Healthcare, Forchheim, Germany). Low-dose chest
CT was performed with 120 kV, 40 mAs, 3260.6 mm detector
collimation, 6460.6 mm slice acquisition, 0.5 s gantry rotation
time, and 1.4 pitch. Images were reconstructed with 5-mm slice
thickness using soft-tissue convolution kernel (B31f).
Epicardial Adipose Tissue Quantification
The amount of EAT volume was assessed by two independent
observers (JZ, GB) unaware of the clinical information, using a
commercially available software tool (Volume, Siemens) based on
attenuation-dependent segmentation methods (Fig. 2). Concor-
dance coefficient between observers was 0.95; with 95% CI
between 0.93–0.96. Observers manually traced the pericardium at
its superior extent (the center of the right pulmonary artery as it
crosses the mid-sagittal plane), at mid-ventricular level, and at the
end of the pericardial sac, which defined the inferior extent of the
pericardial volume. The software automatically interpolated
between the user-defined traces. Automatically traced contours
were manually adjusted to the pericardium if needed. Epicardial
adipose tissue volume was defined as any fat tissue located within
the pericardial sac. A predefined threshold of 2195 to 245 HU
was used to identify voxels corresponding to fat [17]. Figure 2
shows the CT of two matched patients participating in the study
showing their EAT volume measurements.
Coronary Calcium Calcification Evaluation
Each of the four main coronary arteries was identified (left
main, left anterior descending, circumflex, and right). Calcification
in each artery was categorized as absent, mild, moderate, or severe
and scored by the radiologist as 0, 1, 2, or 3, respectively.
Calcification was classified as mild when less than one-third of the
length of the entire artery showed calcification, moderate when
one-third to two-thirds of the artery showed calcification, and
severe when more than two-thirds of the artery showed
calcification. With four arteries thus scored, each subject received
a CAC score ranging from 0 to 12 [25].
Statistical Analysis
Data are summarised as relative frequencies for categorical
variables, mean (SD) for normally distributed variables and
median (25th275th percentile) for non-normal data. Comparisons
between groups were performed using student t-test, Pearson Chi-
square or U-Mann Whitney according to the variables type and
distribution. A multivariate analysis including Charlson comor-
bidity index and COPD diagnosis explored the independent
association with EAT in the entire population. Other variables
with statistical significant difference between groups (lung function,
6 MWD, MMRC, CRP) were not included in the model because
of their colinearity with COPD diagnosis.
The associations of the other CVD risk parameters with EAT
volume were estimated using Spearman correlation coefficients
because of the non-normal distribution of EAT volume values.
Linear regression analyses explored the association of each of the
studied variables and EAT volume. A multiple linear regression
model with EAT volume as the dependent variable and those
parameters that showed statistical significance at the level of 0.05
in the univariable analysis was performed to estimate the
independent association. Significance level was established as a
two-tailed p-Value #0.05. Calculations were made with SPSS
15.0, Chicago, U.S.A.
Results
Seventy current and former smokers without COPD and 171
with COPD participated in the study and their characteristics are
shown in Table 1. Although there were patients in every GOLD
stage of the 2009 severity classification (I: 44%, II: 36%, III: 16%
and IV: 4%), most of them were in GOLD stages I and II.
Compared with controls and as expected for a previously matched
population, patients and controls had similar age, gender
distribution, pack-years history, smoking status, history of diabetes
mellitus, cholesterol levels, history of hypertension, blood pressure
values and Framingham score. As expected, patients with COPD
had abnormal lung function, higher MMRC scores and lower
6 MWD. As previously described [6,10], other CVD risk markers
such as CRP levels and MAB were higher in COPD. Surprisingly,
although higher in COPD patients, CAC was not significantly
different between the groups. Table S1 shows the characteristics of
the COPD patients not selected in the matching process. In
comparison to those selected, these patients had the following
characteristics: greater age, more pack-years, were less likely to be
actively smoking, higher comorbidity index, a similar degree of
severity in terms of lung function, less exercise capacity and a
higher EAT volume. A multivariate analysis exploring the
association of EAT volume with COPD diagnosis after adjusting
for Charlson comorbidity showed that the presence of COPD was
a statistical significant predictor of EAT volume (b coefficient
28.86 95% CI: 7.6–50.1, p = 0.008).
The association of EAT volume with other CVD markers in
COPD patients was: age (r = 0.26, p,0.001), smoking history
(r = 0.27, p,0.001), BMI (r = 0.66, ,0.001), arterial hypertension
(r = 0.28, p = 0.001), diabetes mellitus (r = 0.19, p = 0.003), CRP
(r = 0.32, ,0.001), CAC (r = 0.38, ,0.001) and MAB (r = 0.12,
p = 0.14).
Table 2 shows the univariate analysis exploring the association
of each of the studied parameters with EAT volume in COPD and
Figure 2. CT of two matched patients participating in the study
showing their EAT volume measurements in clear blue.
doi:10.1371/journal.pone.0065593.g002
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in smokers without COPD. Statistical significance was found for
age, pack-years, gender, BMI, FEV1%, 6 MWD, MMRC,
hypertension, and use of anti-hypertensive medication. In smokers
without COPD, we found statistically significant differences in
pack-years, gender, BMI, 6 MWD, HDLc and glucose. Table 3
shows the multivariate analysis that determined the best predictors
of EAT volume in COPD patients and in smokers without COPD,
including those that showed statistical significance in the univariate
analysis. Pack-years, BMI and 6 MWD were the best predictors of
EAT volume in COPD, and only BMI in smokers without COPD.
Discussion
This study showed that in comparison with appropriately
matched controls without COPD, Epicardial Adipose Tissue
volume is greater in COPD patients. We also showed in these
patients, that EAT volume is independently associated with
modifiable CVD risk factors like smoking history, BMI and
decreased exercise capacity.
Abnormal Visceral Abdominal Tissue (VAT) deposition is
receiving increasing attention in patients with COPD for its
potential pathogenic role in CVD in these high risk patients [26].
Previous studies have reported increased visceral fat deposition in
Table 1. Patients characteristics.
Patients characteristics
Smoker COPD P
n 70 171
Age (X 6 SD) 5768 5967 0.056
Gender (%) male/female 80/20 80.5/19.5 1
Pack-year (X 6 SD) 39616 42617 0.31
Current Smoker (%) yes/no 58.6/41.4 55/45 0,67
Framingham Score (%) Median(p25–p75) 17.3 (10.4–20.8) 17.8 (10.4–28.8) 0.65
Charlson Median(p25–p75) 0 (0–1) 1 (1–2) ,0.001
BMI (X 6 SD) 28.265.4 26.964.8 0.074
FEV1/FVC (X 6 SD) 75.564.8 56.8610.5 ,0.001
FEV1 liters (X 6 SD) 3.0560.8 2.1860.8 ,0.001
FEV1% (X 6 SD) 99615.6 73.6621.9 ,0.001
FVC % (X 6 SD) 106617 102.2620.4 0.17
TLC % (X 6 SD) 94.7613 107.7614.3 ,0.001
MMRC 0–4 (%) 80/18.6/1.4/0/0 44.4/31/15.8/8.2/0.6 ,0,001
6 MWD (X 6 SD) 539.67661.7 495.856100 0.003
BODE Quart 1–4 (%) 82.1/10.3/4.8/2.8
Hypertension (%) yes/no 45.7/54.2 32.7/67.3 0.08
Anti-hypertensive treatment (%) yes/no 52.9/47.1 65.5/34.5 0.08
SBP mmHg (X 6 SD) 127.1619.4 126.7619.1 0.86
DBP mmHg (X 6 SD) 76.5612.9 75.22611.2 0.44
DM (%) yes/no 18.6/81.4 14/86 0.43
Glucose Median(p25–p75) 97 (89.5–108) 98 (90.8–111) 0.36
HbA1c Median(p25–p75) 6 (5.7–6.9) 6.1 (5.6–6.7) 0.84
Dyslipemia (%) yes/no 67/33 71/29 0.35
Anti-hyperlipemia treatment (%)yes/no 63/37 70/30 0.36
Total Cholesterol Median(p25–p75) 202 (185–227) 201.5 (170–231.8) 0.56
LDL-C Median(p25–p75) 123 (104–149) 122 (94.8–157.5) 0.79
HDL-C Median(p25–p75) 56 (45–66) 51 (40–64) 0.12
Albumin/Creatinuria index Median(p25–p75) 6.75 (4.4–12.6) 11.8 (5.1–33.9) 0.008
EAT cm3 Median (p25–p75) 129.1 (91.3–170.8) 143.7 (108.3–196.6) 0.028
Coronary Calcium Score Median (p25–p75) 1 (0–2.25) 2 (0–3) 0.062
CRP Median(p25–p75) 0.2 (0.1–0.4) 0.3 (0.2–0.7) 0.041
Systemic corticosteroid treatm (%) yes/no 1.4/98.6 4.1/95.9 0.44
n=Number of participants for each group; BMI = Body Mass Index; FEV1 = Forced Expiratory Volume in the fisrt second; FVC = Forced Vital Capacity; TLC= Total Lung
Capacity; MMRC=Modified Medical rtesearch Council; 6 MWD =6 Minutes Walk Distance; BODE index: BMI, Obstruction, Dyspnea, Exercise; SBP = Systolic Blood
Presure; DBP =Dyastolic Blood Presure; DM=Diabetes Mellitus; LDL-C = Low Density Protein; HDL-C =High Density Protein; EAT = Epicardial Adipose Tissue CRP = C
reactive Protein.
X 6 SD=means 6 Standart Desviation; y/n = Yes/No; p25–p75= interquartile range.
doi:10.1371/journal.pone.0065593.t001
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non-obese mild to moderate COPD patients evaluated with CT
[27,28]. Epicardial Adipose Tissue is the visceral white deposit
located between the myocardium and the visceral pericardium
that has metabolically active properties due to its anatomical and
functional contiguity with the myocardium [12,13]. Biochemical
and thermogenic cardio-protective properties under physiological
conditions have been associated with EAT. However, in patho-
logical circumstances, EAT can affect the myocardium and the
coronary arteries through vasocrine or paracrine secretion of pro-
inflammatory cytokines [29]. EAT has been associated with BMI,
VAT, metabolic risk factors, insulin resistance, and coronary
artery disease [13,30,31,32]. Recently, it has been shown that
EAT volume can independently predict a higher risk of future
incident coronary heart disease in community-based adults
without a history of CVD [17]. Therefore EAT volume measured
on a chest CT has been postulated as a non-invasive tool to
identity high-risk CVD patients in whom specific therapies could
be implemented.
Table 2. Univariate analysis exploring the independent association of the studied variables with EAT volume in patients with
COPD and in smokers.
Univariate with EAT volume as the dependent variable in COPD
Variable Coefficient CI p
Age 2.7 2.5 to 2.9 ,0.001
Pack-years 1.3 0.7 to 2 ,0.001
BMI 9.6 7.5 to 11.6 ,0.001
Gender (female vs male) 254.9 284 to 225.8 ,0.001
FEV1% 20.7 21.2 to 20.1 0.01
6 MWD 20.3 20.4 to 20.1 ,0.001
MMRC 17.3 5.4 to 29.1 0.004
HTN (yes vs no) 37.9 13.1 to 62.7 0.003
Charlson 2.2 24.8 to 9.3 0.54
BODE 5.9 21.4 to 13.3 0.11
Anti-Hypertensive treatment (yes vs no) 44 19.8 to 68.2 ,0.001
Anti-Hyperlipemia treatment (yes vs no) 14.7 211.1 to 40.6 0.26
Total Cholesterol 20.1 20.4 to 0.2 0.58
LDL-C 20.1 20.4 to 0.2 0.46
HDL-C 20,6 21.4 to 0.1 0.08
DM (yes vs no) 29.8 24.3 to 64.0 0.08
Glucose 0.3 20.1 to 0.7 0.14
HbA1c 2.6 29.1 to 14.5 0.65
Univariate with EAT volume as the dependent variable in Smokers without COPD
Age 1.2 20.3 to 2.6 0.12
Pack-years 1.2 0.4 to 1.9 0.04
BMI 7.3 5.2 to 9.4 ,0.001
Gender (female vs male) 246.9 278 to –15.8 0.04
FEV1% 20.4 21.3 to 0.4 0.3
6 MWD 20.4 20.7 to 20.05 0.03
MMRC 24.1 23.2 to 51.3 0.08
HTN (yes vs no) 25 21.5 to 51.5 0.06
Charlson 16 22.5 to 35.5 0.08
Anti-Hypertensive treatment (yes vs no) 22 24.7 to 48.7 0.11
Anti-Hyperlipemia treatment (yes vs no) 22.9 25 to 50.7 0.11
Total Cholesterol 20.2 20.5 to 0.2 0.3
LDL-C 20.3 20.7 to 0.1 0.21
HDL-C 21.4 22.3 to –0.6 0.002
DM (yes vs no) 34.8 21.6 to 71.2 0.06
Glucose 0.7 0.1 to 1.2 0.025
HbA1c 2.8 217.7 to 23.4 0.78
BMI = Body Mass Index; FEV1%= Forced Expiratory Volume in the first second percent; 6 MWD= Six Minutes Walk distance; MMRC=Modified Medical Research Council
Dyspnea Scale; BODE = Body Mass Index, Obstruction, Dyspnea, Exercise; HTN=Hypertension; LDL-C = Low Density Protein Cholesterol; HDL-C =High Density Protein
Cholesterol; DM=Diabetes Mellitus; HbA1c = glycosylated haemoglobin.
doi:10.1371/journal.pone.0065593.t002
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In the present study we have shown that former and current
smokers with a spirometric diagnosis of COPD have increased
EAT volumes in comparison to a similar population matched for
age, pack-years, BMI, smoking status, and other important CVD
risk factors (diabetes mellitus, arterial hypertension, Cholesterol
and CRP). Interestingly, COPD patients in the present study have
higher median and 25–75th percentile EAT values (143.7; 108.3–
196.6 cm3) than those reported in large scale population-based
studies like the Framingham Heart Study Offspring (mean
1246SD 50 cm3) [33], or the MESA study for those with incident
coronary heart disease (mean 1006SD 51 cm3) [17]. Although
there are differences between these trials in their populations
(population based vs. current/former smokers with and without
COPD) and in CT methodology (non-ECG-gated in the
Framingham and in our study vs. ECG-gated in the MESA
study), the fact that EAT volumes in our control group (median
129.1; 25–75th percentiles: 91.3–170.8 cm3) are similar to those
from the population based studies, supports the importance and
validity of our findings.
CT scans of the chest have been traditionally performed in
COPD patients to determine the indication for lung volume
reduction procedures [18]. Lately, CT has also been proposed for
a better characterization of the phenotypic expression of the
disease, and some authors suggest this could be used to tailor
personalised treatments [34]. Furthermore, after the publication of
the results of the NLST study demonstrating that screening a high-
risk population decreases lung cancer specific mortality [35], some
authors have postulated that individuals with COPD and
emphysema could be good candidates for screening programs in
view of their higher risk for lung cancer [36]. As the use of CT for
COPD patients increases, evaluation of EAT volumes may allow
the identification of patients with a higher risk of incident CVD
events, while simultaneously evaluating other important prognostic
radiologic factors such as emphysema [37], bronchiectasis [38],
presence of suspicious nodules [36], or pulmonary artery
enlargement [39].
As has been reported in population-based studies, we show that
in COPD patients EAT volume was associated with other CVD
risk factors. This is important since it implies that the signal found
in population samples is reproducible in high risk cohorts such as
COPD patients, where a CT is much more likely to be obtained
for clinical reasons.
It has been suggested that the CVD risk associated with EAT is
due to two mechanisms. The paracrine secretion of pro-
inflammatory cytokines (adiponectin, leptin, TNFalfa, IL-1beta,
MCP-1, PAI-1, IL-8, IL-6, resistin, angiotensinogen, VEGF) [29],
and the direct release of free fatty acids into the vasa vasorum that
are then transported downstream into the arterial wall [13].
Therefore, as occurs in the general population [32], the significant
association between EAT volume and CAC scores is expected.
MAB levels were also increased in the COPD cohort of this study
[40]. Interestingly, MAB was not associated with EAT volume. A
potential explanation could be that MAB is a measure of general
systemic endothelial dysfunction [41], whereas EAT represents a
local phenomenon affecting primarily the coronary arteries.
The present study also shows that EAT volume in COPD
patients is significantly associated with important CVD risk factors
(age, pack-years, BMI, hypertension), and clinical or physiological
descriptors of COPD (age, BMI, FEV1%, MMRC, 6 MWD). The
multivariate model found that the best predictors of EAT volume
were smoking history as expressed in pack-years, the BMI and
inversely to the 6 MWD. Interestingly in current or former
smokers without COPD, EAT volume was only predicted by BMI
as previously reported [16]. Our findings have important
implications in the daily management of high-risk COPD patients
since all of them are modifiable CVD risk factors. There is
evidence in that EAT deposition is dynamic and that it could be
modified with different interventions such as weight loss achieved
by diet [42] or bariatic surgery [30], and by physical activity [43].
Although not yet studied, it is likely that smoking cessation would
have similar consequences. Strategies aiming at decreasing BMI
will decrease their EAT volume and probably decrease their CVD
risk. Perhaps one of the most interesting findings of this study was
the indirect association between EAT volume and 6 MWD. We
know that 6 MWD reflects daily exercise activity in COPD
patients [44]. It is possible that patients with greater 6 MWD do
more exercise and as a result have lower EAT volumes.
Age and gender were the other patients’ characteristics that
predict EAT volume. Interestingly, Dagvasumberel et al. [45]
recently showed that in 90 patients from Japan with moderate to
severe coronary artery disease (CAD), EAT volume was higher in
men and strongly associated with coronary atherosclerosis. These
authors also found that age was among the predictors of EAT
volume in their study patients. Therefore, the present study
confirms the consistency of these CVD risk factors as predictors of
EAT volume as had previously been shown in a different high-risk
population.
Table 3. Multivariate analysis exploring the independent association of the studied variables with EAT volume in patients with
COPD and in smokers.
Multivariate analysis with EAT as the dependent variable in COPD
Variable Coefficient CI p
Age 1 20.41 to 2.1 0.06
Pack-years 0.6 0.04 to 1.3 0.035
Gender (female vs male) 221.4 244.1 to 1.2 0.06
BMI 7.8 5.7 to 9.9 ,0.001
6 MWD 20.2 20.3 to 20.1 ,0.001
(*) Variables included in the model: Age, Pack-years, Gender, BMI, FEV1%, 6 MWD, MMRC, HTN
Multivariate analysis with EAT as the dependent variable in Smokers without COPD
BMI 9.6 6.7 to 12.5 ,0.001
(*) Variables included in the model: Pack-years, Gender, BMI, 6 MWD, HDL-C, Glucose.
doi:10.1371/journal.pone.0065593.t003
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The reason why EAT deposition is increased in COPD patients
is unclear and was not within the scope of the present work. The
report that other chronic inflammatory diseases like rheumatoid
arthritis, Crohn`s disease and psoriasis have increase deposition of
VAT, suggest a link between inflammation and VAT deposition
[26]. The finding that the Fat Mass and Obesity (FTO) gene has
been positively associated with BMI in COPD patients, suggests a
potential genetic origin since this gene has been associated with
differential fat deposition in the visceral o subcutaneos stores [46].
In obese non-COPD patients, increased visceral relative to
subcutaneous fat has been associated with hypertryglyceridemia
and a decreased rate of glucose utilization [47]. Several reports
propose the link between intermittent hypoxemia and visceral fat
deposition in animal models [48,49], suggesting the potential role
of hypoxic stress in EAT deposition in patients with COPD,
although this has not been demonstrated yet in this population.
There are several limitations to this study. Firstly, it was
performed in patients from a pulmonary clinic, and with specific
clinical and physiological characteristics limited by the randomisa-
tion criteries.Therefore conclusions may not apply to COPD
patients in general. Secondly, most of the patients participating in
this study had mild to moderate disease. Whether the findings can
be extrapolated to patients with more severe disease remains
unknown. However, there is plenty of evidence that the highest
risk for CVD in COPD patients occurs precisely in those with mild
to moderate disease [3,50]. Thirdly, this is a cross sectional study
and therefore the association could be viewed as either a cause or a
consequence. Also the sample size of the present work could be
viewed as a potential limitation, although this is the first report on
EAT in COPD patients. Large longitudinal studies should confirm
that EAT volume is an independent risk factor for CVD events in
COPD patients.
In conclusion, this is the first study showing that EAT volume is
greater in patients with COPD and that it is independently
associated with important modifiable CVD risk factors. If
confirmed this information could have important implications in
the overall management strategy of patients with COPD.
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